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Cigarette smoking and alcohol consumption possibly aﬀect platelet functions. To verify the hypothesis that some α-, β-, and γ-
carbolinecomponentsincigarettesmokeandalcoholicbeveragesmaychangeplateletaggregability,theireﬀectsonhumanplatelets
were determined by aggregometry together with investigating their membrane eﬀects by turbidimetry. Carbolines inhibited
platelet aggregation induced by ﬁve agents with the potency being 3-amino-1,4-dimethyl-5H-pyrido[4,3-b]indole > 3-amino-
1-methyl-5H-pyrido[4,3-b]indole > 1-methyl-9H-pyrido[3,4-b]indole. The most potent 3-amino-1,4-dimethyl-5H-pyrido[4,3-
b]indole showed 50% aggregation-inhibitory concentrations of 6–172μM. Both γ-carbolines interacted with phosphatidylcholine
membranes to lower the lipid phase transition temperature with the potency correlating to the antiplatelet activity, suggesting that
the interaction with platelet membranes to increase their ﬂuidity underlies antiplatelet eﬀects. Given their possible concentration
and accumulation in platelets, γ-a n dβ-carbolines would provide cigarette smokers and alcohol drinkers with reduced platelet
aggregability, and they may be responsible for the occurrence of hemorrhagic diseases associated with heavy smoking and alco-
holics.
1.Introduction
Cigarette smoking has the possibility to aﬀect the functions
of platelets. Platelet aggregation stimulated by collagen is di-
minishedinsmokerscomparedwithnonsmokers,suggesting
that habitual smoking reduces platelet aggregability [1].
Smokers are more susceptible to aspirin in collagen- and
adenosine 5 -diphosphate- (ADP-) induced platelet aggrega-
tion than nonsmokers [2]. Smoking also promotes the plate-
let inhibition mediated by an antiplatelet prodrug clopido-
grel [3]. Cigarette smoking and alcohol drinking are often
characterizedbyconcurrentuse,andalcoholdrinkingisgen-
erally accompanied by an increase in smoking. Platelet de-
fects are also noted in alcoholics [4]. Alcohol consumption is
inversely related to platelet aggregation in response to colla-
gen, epinephrine, and ADP [5], and it reduces platelet aggre-
gability [6, 7]. However, the inﬂuences of cigarette smoking
and alcohol consumption on platelet aggregability appear
to be conﬂicting, with some studies indicating a decrease
and others an increase of aggregation. Platelet aggregation
induced by epinephrine and ADP is increased in habitual
smokers [8, 9]. The platelets of alcoholics are initially hy-
poaggregablebutbecomehyperaggragableafterthecessation
of drinking [10]. ADP-induced platelet aggregation is in-
creased in alcoholics [11].
Cigarette smoke contains a variety of bioactive com-
pounds [9]. Alcoholic beverages are not consumed as pure
ethanol.Therefore,somecomponentsincigarettesmokeand
alcoholic beverage are assumed to inﬂuence the properties
of platelets. The objective of this study was to determine
antiplatelet eﬀects of the assumed compounds and to relate
cigarette smoking and alcohol consumption to hypoaggre-
gability. In addition, their eﬀects on lipid membranes were
investigated to address one possible mode of antiplatelet
action. From the viewpoint of this mechanistic membrane
interaction, an opposite phenomenon, hyperaggregability, in
smokers and alcoholics was also discussed.
Cigarette smoking and alcohol drinking have been re-
ferred to as risk factors for intracerebral hemorrhage, suba-
rachnoid hemorrhage, and hemorrhagic stroke [12–16].
T h e s ef a c t o r sc o r r e l a t ew i t he a c ho t h e r .R e d u c e dp l a t e l e t
aggregability is involved in the development of hemorrhagic2 Journal of Toxicology
complications [17, 18] .T h eo c c u r r e n c eo fh e m o r r h a g ei si n -
creased by heavy cigarette smoking and binge alcohol drink-
ing [12, 19]. A graded increase in risk of intracerebral hemo-
rrhage and hemorrhagic stroke depends on how many ciga-
rettes are smoked [13], and several chemicals in smoke are
likely to relate to the increased risk of intracranial hemo-
rrhage[20].Heavyalcoholdrinking,butnotlight-to-moder-
ate alcohol intake, increases the risk of intracerebral and sub-
arachnoid hemorrhage [12, 14]. These suggest that certain
antiplatelet components in cigarette smoke and alcoholic
beverages are possibly associated with serious hemorrhagic
diseases. This study aimed at discussing such a possibility by
determining their eﬀects on human platelets.
A class of compounds with the pyridoindole structure,
α-,β-,andγ-carbolines,arecontainedincigarettesmokeand
alcoholic beverages. Their levels in mainstream smoke con-
densates are 2.01–10.3ng/cigarette for α-carboline, 0.25–
2.53μg/cigarette for β-carbolines, and 0.29–1.10ng/cigarette
for γ-carbolines [21, 22]. The concentrations of α-a n d
γ-carbolines in combustion smoke samples are 0–1.96
and 0.33–0.74ng/g in mainstream smoke, respectively, but
5.00–6.51 and 0.27–0.37ng/g in sidestream smoke, respec-
tively [23]. β-carbolines show higher levels of 2.10–
8.99μg/cigarette in sidestream smoke compared with 0.36–
4.24μg/cigarette in mainstream smoke [24]. Various alco-
holic beverages contain nM–μMl e v e l so fβ-carbolines
depending on brands [25]. Therefore, it is reasonable to
assume that the in vivo concentrations of carboline com-
pounds may be increased by smoking cigarettes and con-
suming alcoholic beverages. The basal concentrations of
one of β-carbolines, harmane, in plasma (47.7 ± 41.2pM)
and platelets (0.060 ± 0.108pmol/109 platelets) of smokers
are respectively, two- and four-times higher compared with
those (22.5 ± 14.3pMand0.015 ± 0.008pmol/109 platelets)
of nonsmokers, and harmane concentrations increase to
150.4 ± 110.8pMand0.142 ± 0.324pmol/109 platelets after
smoking [26, 27]. Another β-carboline, norharmane, also
shows plasma and platelet concentrations (114.1 ±115.3pM
and0.176±0.078pmol/109 platelets)insmokershigherthan
those(56.5±29.7pMand0.043 ± 0.027pmol/109 platelets)
in nonsmokers, and norharmane concentrations increase to
1.06 ± 0.52nM and 0.245 ± 0.086pmol/109 platelets after
smoking[26].Diﬀerentγ-carbolinesarecontainedinplasma
with the concentrations of 18.8 ± 5.0pMto68.3 ± 24.0pM,
which would markedly increase by smoking cigarettes [28,
29].Theplasmalevelsofnorharmanearehigherinalcoholics
(591.5±154.6pM) compared with a control group (159.9 ±
63.6pM) [25]. Harmane in plasma is increased following
alcohol ingestion [30]. These elevated concentrations appear
to result from inhaling cigarette smoke and drinking alco-
holic beverages [31, 32].
α-, β-, and γ-carbolines exhibit a wide range of bioactiv-
ities such as neuropsychiatric, hallucinogenic, and carcino-
genic, which have been exclusively studied [33–35]. In addi-
tion to these known bioactivities, α-, β-, and γ-carbolines
may exert some eﬀects at the periphery, because they are
found in human blood and platelets. Certain carbolines such
as harmane, harmine, and harmol were recently reported
to show the inhibitory eﬀects on collagen-induced platelet
aggregation [36]. The structure and antiplatelet activity rela-
tionship suggested that the presence of a methyl group in
the pyrido moiety is important for carboline compounds to
inhibit platelet aggregation [37].
In this study, the hypothesis that α-, β-, and γ-carbo-
lines may aﬀect the functions of human platelets was ver-
iﬁed. 2-Amino-3-methyl-9H-pyrido[2,3-b]indole (AMαC),
1-methyl-9H-pyrido[3,4-b]indole (MβC), 3-amino-1,4-di-
methyl-5H-pyrido[4,3-b]indole (ADγC), and 3-amino-1-
methyl-5H-pyrido[4,3-b]indole (AMγC) (see Figure 1 for
their structures) were chosen as tested compounds because
they have a methyl substituent as the antiplatelet activity
determinant in the common pyrido structure and their con-
centrations in cigarette smoke and/or alcoholic beverages are
relatively high [21–25]. Their eﬀects on platelet aggregation
induced by collagen, epinephrine, platelet-activating factor
(PAF), ADP, and thrombin were comparatively determined.
Consequently, γ-carbolines were found to inhibit platelet
aggregation in response to all of the tested inducers which
have diﬀerent aggregation mechanisms, suggesting that the
site of antiplatelet action of γ-carbolines is not conﬁned to
receptors or enzymes for individual aggregation agonists.
The physicochemical property of biomembranes plays a
crucial role in signal transduction and inﬂuences the activity
of platelets. Changes in membrane ﬂuidity induce the inhi-
bition or the promotion of platelet aggregation stimulated
by various aggregants [38–41]. The eﬀects of γ-carbolines on
lipid membranes were studied to get a clue to one of possible
antiplatelet mechanisms.
2.MaterialsandMethods
2.1. Chemicals. AMαC, MβC, ADγC (commercially referred
to as Trp-P-1), and AMγC (commercially referred to
as Trp-P-2) were purchased from Wako Pure Chemicals
(Osaka, Japan). Collagen (MC Medical, Tokyo, Japan), PAF
(Funakoshi, Osaka, Japan), epinephrine (Daiichi Sankyo,
Tokyo, Japan), ADP (MC Medical) and thrombin (Sigma-
Aldrich, St. Louis, Mo, USA) were used for inducing platelet
aggregation. 1,2-Dipalmitoylphosphatidylcholine (DPPC)
was obtained from Avanti Polar Lipids (Alabaster, Ala, USA).
Dimethylsulfoxide(DMSO)ofspectroscopicgrade(Kishida,
Osaka, Japan) and water of liquid chromatographic grade
(Kishida)wereusedforpreparingsamplesolutions.Allother
reagents were of the highest grade available.
2.2. Platelet Aggregation Assay. The experiments were desig-
ned and performed according to the guidelines of the Japa-
nese Pharmacological Society. Human platelet-rich plasma
(PRP) and platelet-poor plasma (PPP) were prepared with
citrated blood which was obtained from healthy male
donors aged 38–48 years (n = 6) of nonsmokers and
nonalcoholics without taking any drugs at least for one
month according to the previous method [42]. Only male
subjects were employed as blood donors because platelet
aggregation induced by collagen, PAF and ADP was diﬀerent
between males and females in the study which evaluated
the comparative eﬀects of the smoking habit and the act of
smoking on platelet aggregability [43]. Sharp increases ofJournal of Toxicology 3
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Figure 1: The structures of α-, β-, and γ-carbolines tested in this study.
the carboline concentrations in plasma and platelets were
found in nonsmokers after 5 minutes following smoking
one cigarette [25–27] and in nonalcoholics 30 minutes after
drinking alcoholic beverages [32]. Therefore, PRP and PPP
were prepared from nonsmokers and nonalcoholics in order
to determine the inherent eﬀects of α-, β-, and γ-carbolines
on platelet aggregation without exposing platelets to carbo-
line compounds. The platelet count of PRP was adjusted to
be 3 × 105 platelets/μL by diluting PRP with PPP. Both PRP
and PPP were used within 3 hours after preparation.
Platelet aggregation was assayed by the same method
as the aggregometry using an antiplatelet reference aspirin
which was recently reported from our laboratory [37]. Since
its methodological validity had been conﬁrmed [44, 45],
this study was performed without using references and the
obtained results were discussed with referring to our recent
report [37]. The aggregation response of PRP was monitored
using a HEMA Tracer 601 aggregometer (Niko Bioscience,
Tokyo,Japan)byanincreaseofpercentlighttransmission(%
T) at 660nm as a function of time. PPP and unstimulated
PRP were deﬁned as 100% T and 0% T,r e s p e c t i v e l y .T h e
tested carbolines were dissolved in and diluted with DMSO
and/or water. After adjustment of % T to 0, 20μL of the
sample solutions were added to 170μL of PRP. Vehicle alone
was added for controls. The volume of DMSO was kept less
than 0.1%–1.0% (v/v) of the total volume so as not to aﬀect
plateletaggregabilityandaggregationinducers.Aftertreating
PRP with each carboline for 1 minute, platelet aggregation
was induced by adding 10μL of the aqueous solutions of
collagen (50μg/mL), PAF (5μM), epinephrine (40μg/mL),
ADP (60μM) or thrombin (5units/mL). The time of their
addition was deﬁned as 0 minute. A maximal % T of aggre-
gation response (Tmax), an area under curve of aggregation
response (AUC, from 0 to 5 minutes) and a single slope
of aggregation response were measured in platelet aggrega-
tion induced by collagen, PAF, ADP, and thrombin. Since
epinephrine showed the biphasic aggregation, ﬁrst Tmax (at
1m i n u t e )a n ds e c o n dTmax (at 5 minutes), ﬁrst AUC (from 0
to1.5minutes)andsecondAUC(from1.5to5minutes),and
slopes of the ﬁrst (% T at 45 seconds) and second (% T at 4
minutes)phasesweremeasured.Thetestedcompoundswere
assayed at various concentrations (1–1000μM). Their %
inhibitions were plotted against their concentrations to
prepare concentration-inhibition curves, from which 50%
inhibitory concentrations were calculated [46].
2.3. Membrane Interaction Assay. The changes in turbidity of
liposomal membrane suspensions reﬂect the thermotropic
phase transition of membrane-constituting phospholipids
from the gel to the liquid crystalline phase and the phase
transitiontemperaturesarealteredbymembrane-interacting
compounds [47]. The membrane interactions of antiplatelet
ADγCa n dA M γC were assayed as reported previously
[48]. Brieﬂy, DPPC liposomes were prepared by hydrating
the dry ﬁlm of DPPC (ﬁnal concentration of 0.4mM)
with water, and then treated with ADγCa n dA M γC( 0 ,
0.5, 1 and 1.5mM for each). The absorption of DPPC
liposome suspensions was measured at 450nm by a UV-260
spectrophotometer equipped with a CPS thermocontroller
(Shimadzu, Kyoto, Japan) as the temperature was increased.
The transition between gel and liquid crystalline phases in
phospholipid liposomes dispersed in the aqueous medium4 Journal of Toxicology
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Figure 2: Concentrations of carbolines to produce 50% inhibition
of the platelet aggregation responses (Tmax,A U C ,a n ds l o p e )t o
collagen. N: Not inhibited by 50% at the indicated concentrations.
Data are presented as mean ± SE (n = 7).
is accompanied by a sudden change in turbidity [49]. The
phase transition temperatures deﬁned as the mid-point of
the abrupt step in absorbance were calculated.
2.4. Statistical Analysis. All results are expressed as mean ±
SE (n = 7 for antiplatelet experiments and n = 6f o r
membrane experiments). Data were analyzed by ANOVA,
followed by post hoc Fisher’s PLSD test using StatView
version 5.0 (SAS Institute, Cary, NC, USA). Values of P<. 05
were considered statistically signiﬁcant.
3. Results
3.1. Antiaggregatory Eﬀect. Carboline compounds aﬀected
human platelets with the potency diﬀerent between sub-
classes. Their inhibitory eﬀects on platelet aggregation in-
duced by collagen, PAF, epinephrine, ADP and thrombin
are shown in Figures 2, 3, 4, 5, 6,a n d7. The compar-
isons showed that γ-carbolines were the most eﬀective in
inhibiting platelet aggregation, followed by less eﬀective β-
carboline, with α-carboline being almost ineﬀective at the
tested concentrations (250 or 500μM). AMαC showed a
50% inhibitory concentration of 499.6 ± 20.3μMo n l yf o r
AUC of aggregation response to ADP. In contrast, ADγCa n d
AMγC decreased Tmax and AUC of aggregation responses
to all of collagen, PAF, epinephrine, ADP, and thrombin.
Both γ-carbolines also decreased the slopes of collagen- and
epinephrine-induced platelet aggregation. When comparing
50% inhibitory concentrations, ADγC was more potent than
AMγC. Even at 10μM or less, ADγC inhibitorily inﬂu-
encedtheaggregabilityofplateletsstimulatedbyPAFandep-
inephrine.
3.2. Membrane Interaction. Antiplatelet γ-carbolines inﬂu-
enced the phase transition of membrane DPPC as shown
in Figure 8.A D γC lowered the phase transition temperature
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Figure 3: Concentrations of carbolines to produce 50% inhibition
of the platelet aggregation responses (Tmax,A U C ,a n ds l o p e )t oP A F .
N: Not inhibited by 50% at the indicated concentrations. Data are
presented as mean ± SE (n = 7).
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Figure 4: Concentrations of carbolines to produce 50% inhibition
of the ﬁrst phase platelet aggregation responses (Tmax,A U C ,a n d
slope) to epinephrine. N: Not inhibited by 50% at the indicated
concentrations. Data are presented as mean ± SE (n = 7).
from a control value of 40.51 ± 0.02◦C to 40.07 ± 0.03◦C
at 500μM, 39.73 ± 0.03◦C at 1mM and 39.45 ± 0.02◦Ca t
1.5mM. AMγC shifted to 40.17 ± 0.03◦C, 39.93 ± 0.03◦C
and 39.73 ± 0.02◦C at 500μM,1mMand1.5mM,respec-
tively. ADγCw a sm o r ee ﬀective in interacting with DPPC
membranes than AMγC( P<. 05 at 500μMa n dP<. 01
at 1 and 1.5mM).
4. Discussion
The comparative studies have revealed that β-a n dγ-carbo-
lines, but not α-carboline, inhibit platelet aggregation in-
duced by ﬁve diﬀerent agents with the potency being
ADγC > AMγC > MβC. The relation between structure andJournal of Toxicology 5
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Figure 5: Concentrations of carbolines to produce 50% inhibition
of the second phase platelet aggregation responses (Tmax,A U C ,a n d
slope) to epinephrine. N: Not inhibited by 50% at the indicated
concentrations. Data are presented as mean ± SE (n = 7).
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Figure 6: Concentrations of carbolines to produce 50% inhibition
oftheplateletaggregationresponses(Tmax,A UC,andslope)toADP .
N: Not inhibited by 50% at the indicated concentrations. Data are
presented as mean ± SE (n = 7).
antiplatelet activity indicates that the basic structure of 5H-
pyrido[4,3-b]indole (γ-carboline) is important for inhibit-
ing platelet aggregation, followed by the structure of 9H-
pyrido[3,4-b]indole (β-carboline). An additional methyl
group in the pyrido moiety provides γ-carbolines with high-
er activity. Since ADγCa n dA M γC themselves do not aggre-
gateplateletsdespitepartlyresemblingserotonininstructure
[50], these γ-carbolines are referred to as potent antiplatelet
compounds.
Antiplatelet γ-carbolines showed relatively low concen-
trations to produce 50% inhibition of AUC of aggregation
response.Sincetheantiplateleteﬀectsofaspirinwererecently
reported by using the same method for platelet aggregation
assay from our laboratory [37], its 50% AUC-inhibitory con-
centrations are usable for comparing with the activity of
Tmax
AUC
Slope
NN
NNN NNN
AMαC MβC AMγC ADγC
0
100
200
300
400
500
5
0
%
i
n
h
i
b
i
t
o
r
y
c
o
n
c
e
n
t
r
a
t
i
o
n
(
μ
M
)
Figure 7: Concentrations of carbolines to produce 50% inhibition
of the platelet aggregation responses (Tmax,A U C ,a n ds l o p e )t o
thrombin. N: Not inhibited by 50% at the indicated concentrations.
Data are presented as mean ± SE (n = 7).
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Figure 8: Eﬀects of antiplatelet γ-carboline on membrane DPPC
phase transition. The absorbance of DPPC liposome suspensions
treated with 0, 0.5, 1, or 1.5mM ADγC was measured at 450nm
with increasing the temperature. Typical traces in multiple mea-
surements are shown.
γ-carbolines. Aspirin showed 116.1 ± 6.4μMf o rc o l l a g e n -
induced, 71.3 ± 5.5μM for epinephrine-induced ﬁrst phase
and 19.3 ± 3.6μM for epinephrine-induced second phase
response, although it did not inhibit PAF-, ADP-, and
thrombin-induced responses by 50% at 500μM. In this
study, ADγCa n dA M γC have been found to show 50%
AUC-inhibitory concentrations of 84.0 ± 7.1 and 179.5 ±
20.7μM, 106.1 ± 8.5 and 153.6 ± 8.5μM, and 21.5 ± 1.9 and
117.2 ± 11.0μM for collagen-induced, epinephrine-induced
ﬁrst phase and epinephrine-induced second phase response,6 Journal of Toxicology
respectively. ADγCa n dA M γC are also eﬀective in inhibiting
AUC of aggregation responses induced by PAF, ADP and
thrombin to show 50% inhibitory concentrations of 6.01 ±
0.58 and 32.0 ± 5.8μM, 65.2 ± 2.4 and 115.5 ± 8.8μM, and
105.8 ± 19.5 and 230.9 ± 25.8μM, respectively. With respect
to platelet aggregation inhibition, γ-carbolines, especially
ADγC, are comparable to or more potent than aspirin.
A question arises as to whether carboline components
actually aﬀect the aggregability of platelets of cigarette
smokers and alcohol drinkers. α-, β-, and γ-carbolines are
contained in mainstream cigarette smoke (≥22ng/cigarette
for AMαC, ≥2.2μg/cigarette for MβC, ≥0.5ng/cigarette for
ADγCa n d≥1.1ng/cigarette for AMγC), and higher levels
are found in sidestream cigarette smoke (≥3.0μg/cigarette
for MβC) [21, 22, 24, 25]. β-carbolines are also present in
various alcoholic beverages at the concentrations of ≥3.2 μM
for MβC[ 25, 51]. Compared with nonsmokers (≥23pM),
the plasma levels of MβC are higher in smokers (≥48pM)
and increase to ≥165pM by smoking a cigarette [25].
The platelet concentrations of MβCa r e≥0.015pmol/109
platelets for nonsmokers but ≥0.060pmol/109 platelets for
smokers, and MβC shows the increasing platelet concentra-
tions to be ≥0.142pmol/109 platelets 13 minutes after smok-
ing [26]. β-carbolines increase in blood rapidly following
cigarette smoking and alcohol drinking, and their concen-
trations in platelets are much higher than in plasma, indi-
cating their signiﬁcant concentration and accumulation in
platelets. The accurate γ-carboline concentrations in plate-
lets of smokers and alcoholics have been unknown. In the
dosingexperimentusingrabbits,however,ADγCwaspresent
in blood, especially in red blood cells, for a long time
after oral dosing [52]. Although aspirin is less potent in
aggregation inhibition than ADγC, it has been frequently
used as an antiplatelet drug. Considering that cigarette
smoke- and alcoholic beverage-derived β-a n dγ-carbolines
areconcentratedand accumulatedin platelets, the possibility
for them to aﬀect platelet aggregability is not necessarily
excluded.
Although the platelet aggregation mechanisms for colla-
gen, PAF, epinephrine, ADP, and thrombin diﬀer, ADγCa n d
AMγC were inhibitory on platelet aggregation induced by
all of these aggregants, and MβC by two aggregants. These
results indicate that γ-a n dβ-carbolines inﬂuence the step
commontodiﬀerentaggregationagonistsinadditiontotheir
speciﬁc action at the receptor and enzyme levels. The physic-
ochemical property of biomembranes, such as ﬂuidity, plays
a crucial role in signal transduction and aﬀects the activity of
platelets. Membrane ﬂuidity modulates platelet aggregability
and membrane-ﬂuidizing compounds attenuate collagen-
and thrombin-induced platelet aggregation [53]. A change
in platelet membrane ﬂuidity is mechanistically related to
various antiplatelet compounds [38, 54].
T h em e m b r a n ee ﬀects of toxins and drugs have been
most frequently studied by measuring ﬂuorescence polar-
ization of liposomal and cellular membranes labeled with
ﬂuorescent probes [37–39, 54]. However, such a method was
not applicable to antiplatelet γ-carbolines, because they are
naturally ﬂuorescent with the maximal excitation and emis-
sion wavelengths almost similar to those of typical ﬂuores-
cent probes. Therefore, turbidimetry was used for them. The
changes in turbidity of liposome suspensions reﬂect the pro-
motion of a gel to liquid crystalline transition of membrane
phospholipids, indicating an increase of membrane ﬂuidity
[47, 48]. Consequently, ADγCa n dA M γCw e r ef o u n dt o
lower the phase transition temperature of membrane DPPC
at 500μM–1.5mM with the potency correlating to their
relative antiplatelet eﬀects. Antiplatelet γ-carbolines appear
to interact with lipid membranes and increase their ﬂuidity
at platelet aggregation-inhibitory concentrations.
The antiplatelet mechanisms previously reported for β-
and γ-carbolines and their relating structures include the
inhibition of aggregation-relevant enzymes and receptors,
and the suppression of cytosolic calcium mobilization and
arachidonicacidliberation.β-andγ-carbolinesinﬂuencecy-
clooxygenase activity and arachidonic acid metabolism to
reduce the production of prostaglandins and thromboxane
[55]. Antiplatelet γ-carbolines (ADγCa n dA M γC) and
β-carbolines (MβC) are the potent inhibitors of mono-
amine oxidase and serotonin uptake of platelets [33, 50].
β-carbolines like MβC inhibit phospholipase Cγ2a n dp r o -
tein tyrosine phosphorylation [36]. Biological membranes
require the lipid bilayer environments optimal for mem-
brane-embedded enzymes, receptors, and transporter sys-
tems. The ﬂuidity changes of platelet membranes modify the
activities of phospholipase, cyclooxygenase, and aggregation
agonists’ receptors with the subsequent inhibition of phos-
phoinositide breakdown, and of prostaglandin and throm-
boxane formation [38, 39]. The increased membrane ﬂuidity
also implies that aggregation-relevant receptors on platelet
membranes are less exposed to the external environment.
The present results suggest that platelet hypoaggregabil-
ity might be induced in smokers and alcoholics by γ-a n d
β-carbolines. However, the inﬂuences of cigarette smoking
and alcohol consumption on platelet aggregation have been
conﬂicting,withsomestudiesreportingareductionofaggre-
gability [1–7] but others an enhancement of aggregability
[8–11]. In contrast to ﬂuid membranes (with increased
ﬂuidity) induced by ADγCa n dA M γC, rigid membranes
(with decreased ﬂuidity) show the enhanced platelet aggre-
gability in response to epinephrine and thrombin [40, 41].
The decreased membrane ﬂuidity renders platelet receptors
more exposed to the external environment and makes the
binding of agonists to the receptors more eﬃciently, result-
ing in an increase of platelet sensitivity to aggregants (hyper-
aggregability) [56, 57]. Varying lipid compositions modify
the ﬂuidity of biomembranes and cholesterol is one of deter-
minants for decreasing membrane ﬂuidity. While the en-
hanced platelet aggregability could be found in chronic
smokers, subjects who had smoked 10 ± 2c i g a r e t t e sp e r
day for 7–10 years showed the decreased ﬂuidity of platelets,
which was due to an increase of cholesterol in platelet mem-
branes [58]. Platelet aggregability in response to ADP and
collagen was enhanced in alcoholics with increasing cho-
lesterolinplateletmembranes[11].Theconﬂictingphenom-
ena, hypoaggregability and hyperaggregability, associated
with cigarette smoking and alcohol consumption appear to
be explained by the biphasic eﬀects of membrane ﬂuidity
changes.Journal of Toxicology 7
Reduced platelet aggregability is important in the devel-
opment of intracranial hemorrhage [17, 28]. Antiplatelet
medication is known to increase the incidence of intracere-
bral hemorrhage, hemorrhagic stroke and other hemorrhag-
ic complication [59, 60] and also increase the recurrence risk
of intracerebral hemorrhage [61]. Intracerebral hemorrhage,
subarachnoid hemorrhage, and hemorrhagic stroke are
closely associated with smoking and drinking habits [12–
16]. The present results suggest the possibility that γ-a n d
β-carboline components in cigarette smoke and/or alcoholic
beverages are pharmacotoxicologically relevant to these seri-
ous hemorrhagic diseases as well as antiplatelet agents by de-
creasing platelet aggregation responses to diﬀerent aggre-
gants.
Another etiological role of cigarette smoking and alcohol
consumption has been indicated in cardiovascular events
[62, 63] although it is conﬂicting similarly to their inﬂuence
on platelet aggregability. Platelet aggregation is patho-
logically related to coronary artery disease and coronary
thrombosis leads to myocardial infarction. The antiplatelet
eﬀects of γ-a n dβ-carbolines are in line with several studies
that cigarette smoking and alcohol drinking protect against
coronary heart disease and also lower the risk of coronary
artery disease and myocardial infarction [63–65]. However,
such eﬀects are inconsistent with other studies that cigarette
smoking is a risk factor for coronary artery disease and binge
alcohol drinking precipitates fatal myocardial infarction [62,
64]. Chronic smokers and heavy drinkers show an increase
of cholesterol in platelet membranes [6, 58], by which the
membraneﬂuidityofplateletsisdecreased.Theaggregability
should be enhanced in such rigid platelet membranes, in-
creasing cardiovascular morbidity.
In conclusion, the reduced platelet aggregability found in
cigarette smokers and alcoholic drinkers would be attribu-
tabletoantiplateletcarbolinecomponentsincigarettesmoke
and alcoholic beverages. γ-a n dβ-carbolines may be respon-
sible for the occurrence of hemorrhagic diseases associated
with heavy smoking and alcoholics by inhibiting platelet
aggregation.
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